A clinical trial will be start soon for Lu-177-PSMA-617 for men with metastatic castration-resistant PC at UCLA and in Houston. They have IRB approval and expect to begin recruiting within a couple of weeks. Anyone who wants to know more about
this exciting therapy, can read about
the latest trials in Germany:/pcnrv.blogspot.com/2016/10/lu-177-psma-617-another-update.html
The details of the clinical trials are described here:/clinicaltrials.gov/ct2/show/NCT03042312
This is a dose-finding trial, so everyone accepted into the study will get the drug (no placebos).
This has an advantage over Xofigo in that it may kill cancer cells in other tissues and systemically rather than in bone only. It may have lower toxicity too. Dry mouth has been a notable side effect.
Other than what's in the clinical trial listing, I can tell you:
• There will
be out-of-pocket costs for the patient (they haven't yet determined the price.). In addition to the Lu-177-PSMA, patients will be required to have a Ga-68-PSMA-PET/CT. UCLA charges $2650 for the PET indicator.
• Patients can get up to 4 treatments (1 every 6 weeks) as long as PSA doesn't rise and there is no evidence of progression. The decision to stop will be up to the physician.
They are accepting 200 men in this trial. It may save you a trip to Germany.
Allen - not an MD
•PSA=7.3, prostate volume=55cc, 8/17 cores G6 5-35% involvement
•SBRT 9 yr onc. results
•SBRT 7 yr QOL results
•treated 10/2010 at age 57 at UCLA,PSA now: 0.1,no lasting urinary, rectal or sexual SEsmy PC blog